BB

Brian Batchelor

Chief Financial Officer

Rocket Pharmaceuticals

Therapeutic Areas

Rocket Pharmaceuticals Pipeline

DrugIndicationPhase
KRESLADI™ (RP-L201)Severe Leukocyte Adhesion Deficiency-I (LAD-I)Approved
RP-A501Danon DiseasePhase 2
RP-L102Fanconi Anemia (FA) complementation group APhase 2
RP-L301Pyruvate Kinase Deficiency (PKD)Phase 1/2
RP-A601PKP2-arrhythmogenic cardiomyopathyPreclinical